Lim Su Lin, Melissa Tay Hui Juan, Ong Kai Wen, Ang Siew Min, Wai Shu Ning, Neo Wen Joo, Yap Qai Ven, Chan Yiong Huak, Khoo Chin Meng, National University Hospital

The effect of healthy ketogenic diet vs calorierestricted diet on weight and metabolic outcomes among individuals with obesity: A randomized controlled trial

Melissa Tay Hui Juan Dietitian National University Hospital Singapore

XXVII IFSO World Congress



CONFLICT OF INTEREST DISCLOSURE

In accordance with «EACCME criteria for the Accreditation of Live Educational Events», please disclose whether you have or not any conflict of interest with the companies:

If you don't have any conflict, please delete the conflict of interest report points:

[X] I have no potential conflict of interest to report

[] I have the following potential conflict(s) of interest to report:

- Type of affiliation / financial interest:
- Receipt of grants/research supports:
- Receipt of honoraria or consultation fees:
- Participation in a company sponsored speaker's bureau:
- Stock shareholder:
- Spouse/partner:
- Other support (please specify):

XXVII IFSO World Congress



Background & Current Literature

- The ketogenic or "keto" diet is a low-carbohydrate, high fat and moderate protein diet plan [1]
- Ketogenic Diet has ↑ popularity [2]
 - Reduces appetite, boosts fat oxidation, and facilitates weight loss.



[1] Harvard School of Public Health. 2024. Diet Review: Ketogenic Diet For Weight Loss2024.

[2] Kirkpatrick CF, Bolick JP, Kris-Etherton PM, Sikand G, Aspry KE, Soffer DE, Willard KE, Maki KC. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: a scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. *Journal of clinical lipidology*. 2019;13(5):689-711.

XXVII IFSO World Congress



Current Literature

A Randomized Trial Comparing a Very Low Carbohydrate Diet and a Calorie-Restricted Low Fat Diet on Body Weight and Cardiovascular Risk Factors in Healthy Women @ [3]

Bonnie J. Brehm 🕿, Randy J. Seeley, Stephen R. Daniels, David A. D'Alessio

Because low carbohydrate diets derive large proportions of calories from protein and fat, there has been considerable concern for their potentially detrimental impact on cardiovascular risk (17). Increased consumption of fat, particularly saturated fat, has been linked to increased plasma concentrations of lipids (18), insulin resistance, glucose intolerance (19, 20), and obesity (21, 22). Therefore, it is possible that many Americans could actually suffer adverse health effects by using very low carbohydrate diets in an attempt to lose weight. To evaluate the effects of a very low

Effects of carbohydrate-restricted diets on lowdensity lipoprotein cholesterol levels in overweight and obese adults: a systematic review and metaanalysis @ [4]





The main concern regarding CRDs, which are potentially high in total fatty acids and SFAs, is their theoretically adverse effect on low-density lipoprotein cholesterol


(LDL-C) levels and, presumably, CVD risk. Saturated fat per se is not associated with

[3] Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. The Journal of Clinical Endocrinology & Metabolism. 2003;88(4):1617-23.

[4] Gjuladin-Hellon T, Davies IG, Penson P, Amiri Baghbadorani R. Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis. *Nutrition reviews*. 2019;77(3):161-80.

XXVII IFSO World Congress





To investigate the effect of a healthy ketogenic diet (HKD) versus a calorie restricted diet(CRD) on weight loss and metabolic outcomes among adults with obesity.

XXVII IFSO World Congress





- Keep within individualised calorie limit per day •
- Keep within 50g net carbohydrates
- Increase fiber intake
- Adequate protein
- Moderate healthy fats
- At least 2L of fluids
- Moderate intensity exercises

XXVII IFSO World Congress

MELEOURNE 202

• Keep within individualised calorie limit per day

- Increase fiber intake
- Adequate protein
- Moderate healthy fats
- At least 2L of fluids
- Moderate intensity exercises





- 7 physical workshop covering similar topics.
 - Content tailored to each group's specific diet specifications.
- Nutritionist Buddy (nBuddy) app



XXVII IFSO World Congress




🗎 13 Jun 2024

RANDOM BLOOD GLUCOSE

►

Methods – nBuddy App Features



XXVII IFSO World Congress



Methods

Primary Outcome:

• \triangle in body weight at 6 months

Secondary Outcome:

- \triangle in body weight at 3 and 12 months
- △ in metabolic profiles at 3, 6 and 12 months
- Dietary intake, physical activity and prescribe medications were tracked as part of secondary outcomes evaluation.




XXVII IFSO World Congress



Methods - Statistical Analysis

- Baseline to 3 months
- Baseline to 6 months
- Baseline to 12 months



XXVII IFSO World Congress



Results – Demographics of study participants at baseline

Table 1: Baseline characteristics of study participants.

Verieble	HKD	CRD	Duralusa	Veriable	HKD	CRD	Duralura
Variable	(n = 41)	(n = 39)	P value ^a	Variable	(n = 41)	(n = 39)	P value ^a
Gender, n (%)				Alanine Transaminase, U/L	34.5±33.1	28.8±23.2	0.377
Male	36 (87.8%)	33 (84.6%)	0.679	Aspartate Transaminase, U/L	27.4±16.1	24.6±9.5	0.357
Female	5 (12.2%)	6 (15.4%)		Co-morbidity, n (%)			
Ethnicity, n (%)				Hypertension			
Chinese	26 (63.4%)	18 (46.2%)	0.255	No	23 (56.1%)	19 (48.7%)	0.509
Malay	10 (24.4%)	9 (23.1%)		Yes	18 (43.9%)	20 (51.3%)	
Indian	3 (7.3%)	7 (17.9%)		Hyperlipidemia			
Others	2 (4.9%)	5 (12.8%)		No	4 (9.8%)	7 (17.9%)	0.288
Age (years)				Yes	37 (90.2%)	32 (82.1%)	
Mean	38.4±8.8	39.4±7.6	0.600	Diabetes			
Range	22-63	28-62		No	33 (80.5%)	34 (87.2%)	0.417
Weight, kg	84.2±14.3	83.3±12.2	0.764	Yes	8 (19.5%)	5 (12.8%)	
Body Mass Index, kg/m ²	32.4±3.9	31.9±3.4	0.546	Transaminitis	0 (15.570)	5 (12.070)	
HbA1c, %	5.7±0.6	5.5±0.3	0.078	No	30 (73.2%)	34 (87.2%)	0.117
Fasting blood glucose, mmol/L	5.7±1.0	5.4±0.5	0.067				0.117
Systolic blood pressure, mmHg	121.7±12.7	122.5±18.5	0.823	Yes Nutrient intake	11 (26.8%)	5 (12.8%)	
Diastolic blood pressure,			0.796		10577.400.0	1705 6 4460 2	0.450
mmHg	78.0±9.8	78.6±10.5	0.750	Calorie, kcal	1857.7 ±400.8	1785.6 ±460.2	0.459
Total cholesterol, mmol/L	5.3±0.9	5.0±1.0	0.158	Protein, g	83.9 ±25.2	75.6 ±16.7	0.086
LDL cholesterol, mmol/L	3.3±0.8	3.2±0.8	0.328	Total fat, g	81.0 ±23.0	75.2 ±22.6	0.259
HDL cholesterol, mmol/L	1.4±0.2	1.3±0.3	0.647	Saturated fat, g	29.7 ±10.3	29.1 ±8.9	0.766
Triglyceride, mmol/L	1.3±0.9	1.1±0.5	0.197	Carbohydrate, g	202.4 ±56.3	202.0 ±58.6	0.979
Data expressed as mean \pm SD for continuous variables; absolute numbers				Net Carbohydrate, g	185.1 ±55.0	186.0 ±56.9	0.940
(percentage) for categorical variables. LDL, Low-density Lipoprotein; HDL,				Sugar, g	53.1 ±29.1	48.9 ±22.3	0.468
High-density Lipoprotein.				Fiber, g	16.9 ±5.9	16.3 ±6.0	0.647
^a Chi-square, Fisher exact, independent samples t-test as appropriate.				Sodium, mg	3402.3 ±1027.4	3189.9 ±1015.1	0.355

XXVII IFSO World Congress



Results – Weight & Metabolic Changes among HKD vs CRD group

Table 2: Primary and secondary outcomes at 3-month, 6-month and 1-year after enrolment using intention-to-treat analysis.

		Mean Change from Baseline Between-group differences ^a				Moon Change from Baceline		Between-group differences ^a					
Outcomes n	n						Outcomes		Mean Change from Baseline		Between-group different		
		HKD	CRD	Mean difference (95% CI)	P value	Cohen d		n	HKD	CRD	Mean difference (95% CI)	P value	Cohen d
		(n = 41)	(n = 39)						(n = 41)	(n = 39)			
Δ Weight, kg					_		Δ Systolic blood pressure, mmHg						
3-month	72	-5.78 ±3.86*	-2.82 ±3.30*	-3.00 (-4.591.40)	<0.001	0.44	3-month	71	-7.08 ±7.42*	-4.12 ±14.46	-3.47 (-7.87- 0.94)	0.121	0.19
6-month	59	-7.84 ±5.21*	-4.17 ±5.59*	-3.64 (-6.390.89)	0.010	0.35	6-month	59	-7.69 ±8.86*	-2.57 ±12.23	-6.38 (-10.732.03)	0.005	0.38
12-month	51	-6.85 ±6.37*	-4.64 ±5.77*	-1.52 (-4.77- 1.74)	0.353	0.13	12-month	51	-4.19 ±10.69	-5.67 ±9.48*	0.36 (-4.73- 5.45)	0.887	0.02
∆ Weight, %							Δ Diastolic blood pressure, mmHg	51	-4.19 ±10.09	-3.07 19.48	0.30 (-4.73- 3.43)	0.887	0.02
3-month	72	-6.80 ±4.24	-3.26 ±3.62	-3.74 (-5.551.93) ^b	<0.001 ^b	0.49 ^b	· _ · _ · · · · ·	74	2.44.17.02*	4.07.005*		0.404	0.10
6-month	59	-9.29 ±5.91	-4.86 ±5.82	-4.56 (-7.591.53) ^b	0.004 ^b	0.39 ^b	3-month	71	-3.11 ±7.03*	-4.97 ±9.85*	1.49 (-2.21- 5.18)	0.424	0.10
12-month	51	-7.93 ±7.65	-5.36 ±6.23	-2.67 (-6.58- 1.25) ^b	0.177 ^b	0.19 ^b	6-month	59	-3.72 ±6.46*	-2.37 ±7.72	-1.58 (-5.01- 1.85)	0.359	0.12
Δ BMI, kg/m²							12-month	51	-2.07 ±8.84	-2.58 ±9.17	0.25 (-4.59- 5.09)	0.917	0.01
3-month	72	-2.21 ±1.41*	-1.03 ±1.17*	-1.23 (-1.830.63)	<0.001	0.48	Δ Total cholesterol, mmol/L						
6-month	59	-3.03 ±2.03*	-1.52 ±1.88	-1.55 (-2.570.53)	0.003	0.40	3-month	71	-0.42 ±0.75*	-0.16 ±0.55	-0.13 (-0.39- 0.13)	0.331	0.12
12-month	51	-2.61 ±2.48*	-1.66 ±1.97*	-0.97 (-2.24- 0.29)	0.128	0.22	6-month	59	-0.29 ±0.75*	-0.08 ±0.67	-0.10 (-0.43- 0.23)	0.551	0.08
∆ ALT, U/L							12-month	51	0.18 ±0.52*	0.26 ±1.00	-0.12 (-0.55- 0.32)	0.594	0.08
3-month	71	-14.38 ±27.83*	-4.91 ±15.90	-3.55 (-7.96- 0.87)	0.113	0.19	Δ HDL-cholesterol, mmol/L						
6-month	59	-18.97 ±32.54*	-5.67 ±23.38	-3.97 (-7.97- 0.03)	0.051	0.26	3-month	71	-0.04 ±0.24	-0.01 ±0.17	-0.01 (-0.11- 0.08)	0.760	0.03
12-month	51	-19.15 ±38.15*	-0.88 ±23.79	-11.08 (-21.920.24)	0.045	0.29	6-month	59	0.05 ±0.19	0.01 ±0.20	0.04 (-0.06- 0.14)	0.406	0.11
∆ AST, U/L							12-month	51	0.09 ±0.19*	0.01 ±0.21	0.08 (-0.03- 0.18)	0.161	0.21
3-month	71	-6.68 ±14.48*	-1.41 ±8.74	-2.26 (-5.14- 0.63)	0.124	0.19	Δ Triglycerides, mmol/L						
6-month	59	-7.62 ±15.52*	0.60 ±11.52	-4.05 (-7.091.01)	0.010	0.35	3-month	71	-0.44 ±0.68*	-0.06 ±0.39	-0.20 (-0.340.06)	0.006	0.33
12-month	51	-8.33 ±18.24*	1.79 ±11.72	-5.51 (-10.380.63)	0.028	0.32	6-month	59	-0.49 ±0.80*	-0.13 ±0.57	-0.17 (-0.42- 0.08)	0.181	0.18
Δ HbA1c, %							12-month	51	-0.57 ±0.88*	-0.04 ±0.66	-0.40 (-0.780.03)	0.036	0.30
3-month	71	-0.27 ±0.29*	-0.11 ±0.19*	-0.09 (-0.18- 0.00)	0.060	0.24	Δ LDL-cholesterol, mmol/L	51	0.57 ±0.08	0.04 ±0.00	0.40 (-0.780.03)	<u></u>	0.50
6-month	59	-0.27 ±0.26*	-0.07 ±0.19	-0.15 (-0.250.04)	0.008	0.37	· · · · · ·	71	0.10.10.00	0.11.10.20	0.01 (0.24, 0.22)	0.024	0.01
12-month	51	-0.27 ±0.28*	-0.12 ±0.21*	-0.09 (-0.21- 0.03)	0.145	0.21	3-month	71	-0.19 ±0.69	-0.11 ±0.39	-0.01 (-0.24- 0.22)	0.924	0.01
∆ Fasting Blood Glucose, mmol/L							6-month	59	-0.12 ±0.60	-0.04 ±0.56	0.00 (-0.27- 0.26)	0.970	0.00
3-month	71	-0.36 ±0.49*	-0.22 ±0.58*	0.00 (-0.22- 0.23)	0.972	0.00	12-month	51	-0.27 ±0.58*	0.07 ±0.76	-0.33 (-0.69- 0.03)	0.073	0.26
6-month	59	-0.42 ±0.48*	-0.24 ±0.52*	-0.10 (-0.35- 0.15)	0.415	0.10	Data expressed as mean ± SD. BMI, Body Mass Index; ALT, Alanine Transaminase; AST, Aspartate Transaminase, HbA1c, Glycated Hemoblogin; HDL, High-density Lipoprotein; LDL, Low-density Lipoprotein.						
12-month	51	-0.32 ±0.50*	-0.21 ±0.46*	-0.01 (-0.28- 0.26)	0.924	0.01	adjusted for gender, age and baseline value of the outcome						

^badjusted for gender and age

* Significant within group changes p values after Benjamini-Hochberg correction with false discovery rate at 0.20 and n=126

Significant p values after Benjamini-Hochberg correction with false discovery rate at 0.20 and n=66 in bold

XXVII IFSO World Congress



Results – **Participants with** ≥ 5% and ≥ 10% weight loss

Table 3: Odds ratio of HKD group achieving weight loss at 3-month, 6-month and 1-year in comparison to CRD group.

	Weight loss <5%	Weight loss ≥5%	OR (95% CI) ^a	p-value
3-month				
HKD	15 (40.5%)	22 (59.5%)	3.5 (1.3-9.4)	<mark>0.014</mark>
CRD	24 (68.6%)	11 (31.4%)	1.0	
6-month				
HKD	8 (27.6%)	21 (72.4%)	5.6 (1.8- 17.6)	<mark>0.003</mark>
CRD	20 (66.7%)	10 (33.3%)	1.0	
12-month				
HKD	11 (40.7%)	16 (59.3%)	1.5 (0.5- 4.7)	0.474
CRD	12 (50.0%)	12 (50.0%)	1.0	
	Weight loss <10%	Weight loss ≥10%	OR (95% CI) ^a	p-value
3-month			\sim	
HKD	28 (75.7%)	9 (24.3%)	(14.5)(1.6-131.9)	<mark>0.017</mark>
CRD	34 (97.1%)	1 (2.9%)	1.0	
6-month				
HKD	16 (55.2%)	13 (44.8%)	(4.9)1.3-17.8)	<mark>0.017</mark>
CRD	25 (83.3%)	5 (16.7%)	1.0	
12-month			$\overline{}$	
HKD	16 (59.3%)	11 (40.7%)	3.2 (0.8-12.3)	0.099
CRD	19 (79.2%)	5 (20.8%)	1.0	

^aadjusted for gender and age


Significant p values after Benjamini-Hochberg correction with false discovery rate at 0.20 and n=6 in bold

XXVII IFSO World Congress



Results – Correlation of net carbohydrate intake and weight loss

Figure 1: Correlation between net carbohydrate intake and weight loss in the HKD group at (i) 3-month, (ii) 6-month and (iii) 1-year.



XXVII IFSO World Congress







Figure 2: Correlation between calorie intake and weight loss in the CRD and HKD group at 3-month, 6-month and 1-year.

Results – Average macronutrients consumption among HKD and CRD group

Figure 3: Macronutrient intake distributions in the CRD and HKD group at baseline, 3-month, 6-month and 1-year.



Results – Self Reported Symptoms by HKD and CRD group

Table 4: Self-reported symptoms experienced by participants at 3 months, 6 months and 1 year post-intervention.

Symptoms Experienced Days/Week (Number of responders)		HKD		CRD			
	3-month	6-month	1-year	3-month	6-month	1-year	
Hunger Pangs	2.5 (22)	2.1 (21)	2.7 (8)	2.6 (21)	2.2 (18)	2.4 (8)	
Nausea	1.5 (4)	2 (1)	0.5 (1)	1 (1)	0 (0)	1.5 (1)	
Headache	1.4 (8)	2 (3)	1.8 (5)	1.7 (3)	1.4 (5)	2.5 (3)	
Constipation	2.2 (15)	2 (9)	2.2 (6)	2 (11)	2.4 (6)	1.75 (6)	
Bad Breath	2.2 (6)	2 (2)	1.75 (2)	1 (2)	3 (1)	0 (0)	
Decreased concentration	2 (1)	1.5 (2)	3.25 (2)	2.5 (4)	1.5 (2)	0 (0)	

XXVII IFSO World Congress





HKD is helpful with achieving a clinically meaning weight reduction and improving cardiometabolic outcomes compared to CRD



XXVII IFSO World Congress



Acknowledgments

Dr Lim Su Lin Ms Ong Kai Wen Ms Ang Siew Min Ms Wai Shu Ning Ms Neo Wen Joo Ms Yap Qai Ven **Dr Chan Yiong Huak** Dr Khoo Chin Meng

XXVII IFSO World Congress

